Exelixis FY2026 EPS Forecast Boosted by Leerink Partnrs

Exelixis, Inc. (NASDAQ:EXEL) – Equities researchers at Leerink Partnrs increased their FY2026 earnings estimates for Exelixis in a research report issued to clients and investors on Wednesday, March 26th. Leerink Partnrs analyst A. Berens now expects that the biotechnology company will post earnings per share of $2.56 for the year, up from their previous estimate of $2.54. The consensus estimate for Exelixis’ current full-year earnings is $2.04 per share.

Other analysts have also issued research reports about the stock. Brookline Capital Management began coverage on shares of Exelixis in a research note on Monday, December 23rd. They set a “buy” rating for the company. Stephens reaffirmed an “equal weight” rating and set a $29.00 price objective on shares of Exelixis in a research report on Wednesday, February 12th. Guggenheim reissued a “buy” rating and issued a $42.00 target price on shares of Exelixis in a report on Wednesday, February 12th. Piper Sandler upped their target price on Exelixis from $37.00 to $38.00 and gave the company an “overweight” rating in a report on Wednesday, February 12th. Finally, Oppenheimer downgraded Exelixis from an “outperform” rating to a “market perform” rating and cut their price target for the stock from $41.00 to $33.00 in a report on Friday, January 24th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $37.59.

Exelixis Trading Down 1.4 %

EXEL stock opened at $36.39 on Monday. The stock’s 50 day simple moving average is $35.72 and its 200 day simple moving average is $33.46. Exelixis has a 12-month low of $20.14 and a 12-month high of $40.02. The firm has a market cap of $10.18 billion, a P/E ratio of 20.56, a P/E/G ratio of 1.13 and a beta of 0.57.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%.

Insiders Place Their Bets

In other Exelixis news, EVP Patrick J. Haley sold 52,636 shares of Exelixis stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $36.98, for a total transaction of $1,946,479.28. Following the transaction, the executive vice president now owns 303,310 shares of the company’s stock, valued at $11,216,403.80. The trade was a 14.79 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Mary C. Beckerle sold 12,210 shares of the company’s stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $34.88, for a total value of $425,884.80. Following the completion of the transaction, the director now owns 30,406 shares in the company, valued at $1,060,561.28. This represents a 28.65 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 140,343 shares of company stock worth $5,177,234 over the last ninety days. 2.85% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. NorthCrest Asset Manangement LLC increased its stake in shares of Exelixis by 14.9% in the fourth quarter. NorthCrest Asset Manangement LLC now owns 13,536 shares of the biotechnology company’s stock worth $451,000 after acquiring an additional 1,758 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in Exelixis in the fourth quarter valued at about $11,998,000. Forum Financial Management LP acquired a new position in Exelixis in the 4th quarter worth about $241,000. GF Fund Management CO. LTD. purchased a new stake in shares of Exelixis during the 4th quarter worth about $200,000. Finally, Neo Ivy Capital Management lifted its holdings in shares of Exelixis by 427.8% during the 4th quarter. Neo Ivy Capital Management now owns 53,892 shares of the biotechnology company’s stock valued at $1,794,000 after buying an additional 43,682 shares during the last quarter. 85.27% of the stock is owned by hedge funds and other institutional investors.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.